Outset Medical Files 8-K
Ticker: OM · Form: 8-K · Filed: May 6, 2024 · CIK: 1484612
| Field | Detail |
|---|---|
| Company | Outset Medical, INC. (OM) |
| Form Type | 8-K |
| Filed Date | May 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
Outset Medical filed a routine 8-K, no major news.
AI Summary
Outset Medical, Inc. filed an 8-K on May 6, 2024, to report other events and financial statements. The filing does not contain specific financial details or significant business updates beyond its routine reporting nature.
Why It Matters
This 8-K filing indicates routine corporate reporting by Outset Medical, Inc. to the SEC, without disclosing new material events.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting events and financial statements, with no indication of new risks or material adverse information.
Key Players & Entities
- Outset Medical, Inc. (company) — Registrant
- May 6, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 3052 Orchard Dr., San Jose, California 95134 (address) — Principal Executive Offices
- Home Dialysis Plus, Ltd. (company) — Former Company Name
FAQ
What is the primary purpose of this 8-K filing for Outset Medical, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of May 6, 2024.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is May 6, 2024.
What is the principal executive office address for Outset Medical, Inc.?
The principal executive office address for Outset Medical, Inc. is 3052 Orchard Dr., San Jose, California 95134.
What was Outset Medical, Inc.'s former company name?
Outset Medical, Inc.'s former company name was Home Dialysis Plus, Ltd.
In which state was Outset Medical, Inc. incorporated?
Outset Medical, Inc. was incorporated in Delaware.
Filing Stats: 451 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-05-06 08:10:10
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share OM The Nasdaq S
Filing Documents
- om-20240506.htm (8-K) — 45KB
- om-ex99_1.htm (EX-99.1) — 11KB
- 0000950170-24-053215.txt ( ) — 174KB
- om-20240506.xsd (EX-101.SCH) — 30KB
- om-20240506_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On May 6, 2024, Outset Medical, Inc. (the "Company") announced that the United States Food and Drug Administration has granted 510(k) clearance of TabloCart with Prefiltration. The Company has resumed distribution of TabloCart with Prefiltration and has product available to ship to customers in the United States. A copy of the press release is attached hereto as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release entitled "Outset Medical's TabloCart with Prefiltration Receives FDA 510(k) Clearance" dated May 6, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Outset Medical, Inc. Date: May 6, 2024 By: /s/Nabeel Ahmed Nabeel Ahmed Chief Financial Officer